
## **Bill Deakin**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3712745/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nature Reviews Drug Discovery, 2012, 11, 141-168.	46.4	960
2	Dissociable Deficits in the Decision-Making Cognition of Chronic Amphetamine Abusers, Opiate Abusers, Patients with Focal Damage to Prefrontal Cortex, and Tryptophan-Depleted Normal Volunteers Evidence for Monoaminergic Mechanisms. Neuropsychopharmacology, 1999, 20, 322-339.	5.4	946
3	5-HT and mechanisms of defence. Journal of Psychopharmacology, 1991, 5, 305-315.	4.0	868
4	Neuronal correlates of theory of mind and empathy: A functional magnetic resonance imaging study in a nonverbal task. Neurolmage, 2006, 29, 90-98.	4.2	838
5	Response inhibition and impulsivity: an fMRI study. Neuropsychologia, 2003, 41, 1959-1966.	1.6	496
6	Differential Response Patterns in the Striatum and Orbitofrontal Cortex to Financial Reward in Humans: A Parametric Functional Magnetic Resonance Imaging Study. Journal of Neuroscience, 2003, 23, 303-307.	3.6	472
7	Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. Journal of Psychopharmacology, 2000, 14, 3-20.	4.0	367
8	Effects of lesions of the orbitofrontal cortex on sensitivity to delayed and probabilistic reinforcement. Psychopharmacology, 2002, 160, 290-298.	3.1	353
9	Glutamate and the Neural Basis of the Subjective Effects of Ketamine. Archives of General Psychiatry, 2008, 65, 154.	12.3	298
10	Neurotransmitter receptors and monoamine metabolites in the brains of patients with Alzheimer-type dementia and depression, and suicides. Neuropharmacology, 1984, 23, 1561-1569.	4.1	296
11	Affective Cognition and its Disruption in Mood Disorders. Neuropsychopharmacology, 2011, 36, 153-182.	5.4	264
12	Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology, 2020, 34, 3-78.	4.0	259
13	State-dependent changes in hippocampal grey matter in depression. Molecular Psychiatry, 2013, 18, 1265-1272.	7.9	257
14	The Effect of Citalopram Pretreatment on Neuronal Responses to Neuropsychological Tasks in Normal Volunteers: An fMRI Study. Neuropsychopharmacology, 2005, 30, 1724-1734.	5.4	250
15	Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment. Journal of Psychopharmacology, 2012, 26, 1185-1193.	4.0	247
16	Collaborative meta-analysis finds no evidence of a strong interaction between stress and 5-HTTLPR genotype contributing to the development of depression. Molecular Psychiatry, 2018, 23, 133-142.	7.9	247
17	The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics?. Journal of Psychopharmacology, 2001, 15, 37-46.	4.0	209
18	The neural basis of maternal responsiveness to infants: an fMRI study. NeuroReport, 2004, 15, 1825-1829.	1.2	209

#	Article	IF	CITATIONS
19	Neural Activation during Covert Processing of Positive Emotional Facial Expressions. NeuroImage, 1996, 4, 194-200.	4.2	200
20	Functional anatomy of verbal fluency in people with schizophrenia and those at genetic risk. British Journal of Psychiatry, 2000, 176, 52-60.	2.8	186
21	Resting state networks in major depressive disorder. Psychiatry Research - Neuroimaging, 2014, 224, 139-151.	1.8	180
22	Abnormal frontal activations related to decision-making in current and former amphetamine and opiate dependent individuals. Psychopharmacology, 2005, 180, 612-623.	3.1	174
23	Increased Amygdala Responses to Sad But Not Fearful Faces in Major Depression: Relation to Mood State and Pharmacological Treatment. American Journal of Psychiatry, 2012, 169, 841-850.	7.2	163
24	Bio-social origins of depression in the community. British Journal of Psychiatry, 2002, 180, 168-173.	2.8	159
25	Expression of hippocampal brain-derived neurotrophic factor and its receptors in Stanley consortium brains. Journal of Psychiatric Research, 2009, 43, 1175-1184.	3.1	154
26	CNR1 Gene is Associated with High Neuroticism and Low Agreeableness and Interacts with Recent Negative Life Events to Predict Current Depressive Symptoms. Neuropsychopharmacology, 2009, 34, 2019-2027.	5.4	153
27	NMDA receptor subunit NRI and postsynaptic protein PSD-95 in hippocampus and orbitofrontal cortex in schizophrenia and mood disorder. Schizophrenia Research, 2005, 80, 323-330.	2.0	143
28	The CREB1-BDNF-NTRK2 Pathway in Depression: Multiple Gene-Cognition-Environment Interactions. Biological Psychiatry, 2011, 69, 762-771.	1.3	142
29	Temporal discounting in major depressive disorder. Psychological Medicine, 2014, 44, 1825-1834.	4.5	134
30	The benefit of minocycline on negative symptoms of schizophrenia in patients with recent-onset psychosis (BeneMin): a randomised, double-blind, placebo-controlled trial. Lancet Psychiatry,the, 2018, 5, 885-894.	7.4	133
31	Neurobiological substrates of antisocial and borderline personality disorder: preliminary results of a functional fMRI study. Criminal Behaviour and Mental Health, 2004, 14, 39-54.	0.8	131
32	Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia: a naturalistic caseseries outcome study. Journal of Psychopharmacology, 2001, 15, 297-301.	4.0	122
33	Studies on possible mechanisms of action of electroconvulsive therapy; effects of repeated electrically induced seizures on rat brain receptors for monoamines and other neurotransmitters. Psychopharmacology, 1981, 73, 345-349.	3.1	121
34	A neuroendocrine study of 5HT function in depression: evidence for biological mechanisms of endogenous and psychosocial causation. Psychopharmacology, 1990, 101, 85-92.	3.1	121
35	Neuronal effects of acute citalopram detected by pharmacoMRI. Psychopharmacology, 2005, 180, 680-686.	3.1	121
36	Citalopram modulation of neuronal responses to aversive face emotions: a functional MRI study. NeuroReport, 2007, 18, 1351-1355.	1.2	118

#	Article	IF	CITATIONS
37	The role of self-blame and worthlessness in the psychopathology of major depressive disorder. Journal of Affective Disorders, 2015, 186, 337-341.	4.1	115
38	Instrumental responding for rewards is associated with enhanced neuronal response in subcortical reward systems. NeuroImage, 2004, 21, 984-990.	4.2	113
39	Medial orbitofrontal cortex codes relative rather than absolute value of financial rewards in humans. European Journal of Neuroscience, 2008, 27, 2213-2218.	2.6	112
40	State-dependent alteration in face emotion recognition in depression. British Journal of Psychiatry, 2011, 198, 302-308.	2.8	111
41	Minocycline and celecoxib as adjunctive treatments for bipolar depression: a multicentre, factorial design randomised controlled trial. Lancet Psychiatry,the, 2020, 7, 515-527.	7.4	110
42	Autoradiography with [3H]8-OH-DPAT reveals increases in 5-HT1A receptors in ventral prefrontal cortex in schizophrenia. Biological Psychiatry, 1996, 39, 919-928.	1.3	109
43	Comparing the actions of lanicemine and ketamine in depression: key role of the anterior cingulate. European Neuropsychopharmacology, 2016, 26, 994-1003.	0.7	100
44	Serotonergic modulation of neuronal responses to behavioural inhibition and reinforcing stimuli: an fMRI study in healthy volunteers. European Journal of Neuroscience, 2006, 23, 552-560.	2.6	99
45	Inflammation and Brain Structure in Schizophrenia and Other Neuropsychiatric Disorders. JAMA Psychiatry, 2022, 79, 498.	11.0	99
46	Expression of neuronal nitric oxide synthase mRNA in stress-related brain areas after restraint in rats. Neuroscience Letters, 2000, 289, 123-126.	2.1	96
47	Effects of orbital prefrontal cortex dopamine depletion on inter-temporal choice: a quantitative analysis. Psychopharmacology, 2004, 175, 206-14.	3.1	96
48	Effects of ritanserin on aversive classical conditioning in humans. Psychopharmacology, 1991, 104, 220-224.	3.1	93
49	A review of clinical efficacy of 5-HT 1A agonists in anxiety and depression. Journal of Psychopharmacology, 1993, 7, 283-289.	4.0	90
50	Adult neurogenesis and schizophrenia: A window on abnormal early brain development?. Schizophrenia Research, 2007, 90, 1-14.	2.0	88
51	Role of the Orbitofrontal Cortex in Reinforcement Processing and Inhibitory Control: Evidence from functional magnetic resonance imaging Studies in Healthy Human Subjects. International Review of Neurobiology, 2005, 65, 89-116.	2.0	87
52	Glial fibrillary acidic protein and glutamine synthetase in subregions of prefrontal cortex in schizophrenia and mood disorder. Neuroscience Letters, 2006, 404, 276-281.	2.1	85
53	Thought disorder in schizophrenia is associated with both executive dysfunction and circumscribed impairments in semantic function. Psychological Medicine, 2006, 36, 475-484.	4.5	85
54	Brain galanin system genes interact with life stresses in depression-related phenotypes. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E1666-73.	7.1	83

#	Article	IF	CITATIONS
55	Quantitative frontal and temporal structural MRI studies in personality-disordered offenders and control subjects. Psychiatry Research - Neuroimaging, 2002, 116, 133-149.	1.8	82
56	Electrophysiological evidence that drug cues have greater salience than other affective stimuli in opiate addiction. Journal of Psychopharmacology, 2008, 22, 836-842.	4.0	82
57	A comparison of salivary cortisol in chronic fatigue syndrome, community depression and healthy controls. Journal of Affective Disorders, 1998, 47, 191-194.	4.1	81
58	Regional changes in [3H]d-aspartate and [3H]TCP binding sites in Alzheimer's disease brains. Brain Research, 1988, 462, 76-82.	2.2	79
59	Attenuated responses to emotional expressions in women with generalized anxiety disorder. Psychological Medicine, 2011, 41, 1009-1018.	4.5	79
60	Neuronal correlates of reward and loss in Cluster B personality disorders: A functional magnetic resonance imaging study. Psychiatry Research - Neuroimaging, 2007, 156, 151-167.	1.8	77
61	Ketamine and other potential glutamate antidepressants. Psychiatry Research, 2015, 225, 1-13.	3.3	77
62	A specific role for serotonin in overcoming effort cost. ELife, 2016, 5, .	6.0	77
63	Assessing human 5-HT function in vivo with pharmacoMRI. Neuropharmacology, 2008, 55, 1029-1037.	4.1	75
64	Periaqueductal grey lesions reduce morphine analgesia in the rat. Neuroscience Letters, 1977, 4, 99-103.	2.1	74
65	Effects of quinolinic acid-induced lesions of the nucleus accumbens core on inter-temporal choice: a quantitative analysis. Psychopharmacology, 2007, 195, 71-84.	3.1	72
66	Self-blame–Selective Hyperconnectivity Between Anterior Temporal and Subgenual Cortices and Prediction of Recurrent Depressive Episodes. JAMA Psychiatry, 2015, 72, 1119.	11.0	69
67	The effect of orbital prefrontal cortex lesions on performance on a progressive ratio schedule: implications for models of inter-temporal choice. Behavioural Brain Research, 2005, 156, 145-152.	2.2	68
68	5 -HT, antidepressant drugs and the psychosocial origins of depression. Journal of Psychopharmacology, 1996, 10, 31-38.	4.0	67
69	A two-process theory of schizophrenia: Evidence from studies in post-mortem brain. Journal of Psychiatric Research, 1997, 31, 277-295.	3.1	67
70	Comparison of the analgesic properties of lipotropin C-Fragment and stabilized enkephalins in the rat. Biochemical and Biophysical Research Communications, 1977, 74, 748-754.	2.1	66
71	The role of serotonin in panic, anxiety and depression. International Clinical Psychopharmacology, 1998, 13, S1-S6.	1.7	64
72	The role of serotonin in reward, punishment and behavioural inhibition in humans: Insights from studies with acute tryptophan depletion. Neuroscience and Biobehavioral Reviews, 2014, 46, 365-378.	6.1	59

#	Article	IF	CITATIONS
73	Regional default mode network connectivity in major depressive disorder: modulation by acute intravenous citalopram. Translational Psychiatry, 2019, 9, 116.	4.8	59
74	Neuronal correlates and serotonergic modulation of behavioural inhibition and reward in healthy and antisocial individuals. Journal of Psychiatric Research, 2010, 44, 123-131.	3.1	58
75	Vortioxetine reduces BOLD signal during performance of the N-back working memory task: a randomised neuroimaging trial in remitted depressed patients and healthy controls. Molecular Psychiatry, 2018, 23, 1127-1133.	7.9	58
76	An investigation of the role of the locus coeruleus in anxiety and agonistic behaviour. Brain Research, 1979, 169, 411-420.	2.2	55
77	Reversed Frontotemporal Connectivity During Emotional Face Processing in Remitted Depression. Biological Psychiatry, 2012, 72, 604-611.	1.3	55
78	Role of the orbital prefrontal cortex in choice between delayed and uncertain reinforcers: a quantitative analysis. Behavioural Processes, 2003, 64, 239-250.	1.1	54
79	Visual information processing deficits as biomarkers of vulnerability to schizophrenia: An event-related potential study in schizotypy. Neuropsychologia, 2010, 48, 2205-2214.	1.6	54
80	Neurobiology of schizophrenia. Current Opinion in Psychiatry, 1996, 9, 50-56.	6.3	54
81	Variations in the cannabinoid receptor 1 gene predispose to migraine. Neuroscience Letters, 2009, 461, 116-120.	2.1	53
82	The origins of â€~5-HT and mechanisms of defence' by Deakin and Graeff: A personal perspective. Journal of Psychopharmacology, 2013, 27, 1084-1089.	4.0	53
83	Ketamine, but Not the NMDAR Antagonist Lanicemine, Increases Prefrontal Global Connectivity in Depressed Patients. Chronic Stress, 2018, 2, 247054701879610.	3.4	52
84	Comorbidities in the diseasome are more apparent than real: What Bayesian filtering reveals about the comorbidities of depression. PLoS Computational Biology, 2017, 13, e1005487.	3.2	51
85	Dopamine and Glutamate in Antipsychotic-Responsive Compared With Antipsychotic-Nonresponsive Psychosis: A Multicenter Positron Emission Tomography and Magnetic Resonance Spectroscopy Study (STRATA). Schizophrenia Bulletin, 2021, 47, 505-516.	4.3	51
86	Characterization of a psychophysiological model of classical fear conditioning in healthy volunteers: influence of gender, instruction, personality and placebo. Psychopharmacology, 1991, 104, 231-236.	3.1	50
87	Diminished Neural and Cognitive Responses to Facial Expressions of Disgust in Patients with Psoriasis: A Functional Magnetic Resonance Imaging Study. Journal of Investigative Dermatology, 2009, 129, 2613-2619.	0.7	49
88	Machine learning algorithm accurately detects fMRI signature of vulnerability to major depression. Psychiatry Research - Neuroimaging, 2015, 233, 289-291.	1.8	49
89	A Positron Emission Tomography Study of the 5-Ht1A Receptor in Schizophrenia and during Clozapine Treatment. Journal of Psychopharmacology, 2004, 18, 346-354.	4.0	48
90	Effects of lesions of the nucleus accumbens core on inter-temporal choice: Further observations with an adjusting-delay procedure. Behavioural Brain Research, 2009, 202, 272-277.	2.2	48

#	Article	IF	CITATIONS
91	Enhanced 5-hydroxytryptamine and dopamine-mediated behavioural responses following convulsions $\hat{e}^{"}$ III the effects of monoamine antagonists and synthesis inhibitors on the ability of electroconvulsive shock to enhance responses. Neuropharmacology, 1980, 19, 907-914.	4.1	47
92	Loss of cortical GABA uptake sites in Alzheimer's disease. Journal of Neural Transmission, 1988, 71, 219-226.	2.8	47
93	The effect of acute citalopram on face emotion processing in remitted depression: A pharmacoMRI study. European Neuropsychopharmacology, 2011, 21, 140-148.	0.7	47
94	Interaction between a history of depression and rumination on neural response to emotional faces. Psychological Medicine, 2011, 41, 1845-1855.	4.5	47
95	Electrophysiological evidence of the motivational salience of drug cues in opiate addiction. Psychological Medicine, 2007, 37, 1203-1209.	4.5	46
96	Social-economical decision making in current and remitted major depression. Psychological Medicine, 2015, 45, 1301-1313.	4.5	46
97	Sodium dependent d-[3H]aspartate binding in cerebral cortex in patients with Alzheimer's and Parkinson's diseases. Neuroscience Letters, 1987, 79, 213-217.	2.1	45
98	Cognition and the inhibitory control of saccades in schizophrenia and Parkinson's disease. Progress in Brain Research, 2002, 140, 449-466.	1.4	44
99	Quantification of glutathione in the human brain by <scp>MR</scp> spectroscopy at 3 <scp>T</scp> esla: Comparison of <scp>PRESS</scp> and <scp>MEGAâ€PRESS</scp> . Magnetic Resonance in Medicine, 2017, 78, 1257-1266.	3.0	44
100	Analgesic activity of lipotropin C fragment depends on carboxyl terminal tetrapeptide. Nature, 1977, 269, 167-168.	27.8	43
101	Increased density of entorhinal glutamate-immunoreactive vertical fibers in schizophrenia. Journal of Neural Transmission, 1996, 103, 503-507.	2.8	43
102	Power calculations for multicenter imaging studies controlled by the false discovery rate. Human Brain Mapping, 2010, 31, 1183-1195.	3.6	43
103	Evaluation of a psychophysiological model of classical fear conditioning in anxious patients. Psychopharmacology, 1991, 104, 215-219.	3.1	42
104	Abnormal persistence of cerebellar serotonin-1A receptors in schizophrenia suggests failure to regress in neonates. Journal of Neural Transmission, 1998, 105, 305-315.	2.8	42
105	Co-operation with another player in a financially rewarded guessing game activates regions implicated in theory of mind. Social Neuroscience, 2006, 1, 385-395.	1.3	42
106	A Functional Magnetic Resonance Imaging Paradigm of Expressed Emotion in Schizophrenia. Journal of Nervous and Mental Disease, 2011, 199, 25-29.	1.0	41
107	Proneness to Decreased Negative Emotions in Major Depressive Disorder when Blaming Others rather than Oneself. Psychopathology, 2013, 46, 34-44.	1.5	41
108	Increased Amygdala Response to Shame in Remitted Major Depressive Disorder. PLoS ONE, 2014, 9, e86900.	2.5	41

#	Article	IF	CITATIONS
109	Lack of deleterious effects of buspirone on cognition in healthy male volunteers. Journal of Psychopharmacology, 2007, 21, 210-215.	4.0	40
110	A voxelâ€based morphometric MRI study in men with borderline personality disorder: preliminary findings. Criminal Behaviour and Mental Health, 2009, 19, 64-72.	0.8	40
111	A validation of cognitive biomarkers for the early identification of cognitive enhancing agents in schizotypy: A three-center double-blind placebo-controlled study. European Neuropsychopharmacology, 2012, 22, 469-481.	0.7	40
112	Significance of risk polymorphisms for depression depends on stress exposure. Scientific Reports, 2018, 8, 3946.	3.3	39
113	Impaired regulatory T cell control of astroglial overdrive and microglial pruning in schizophrenia. Neuroscience and Biobehavioral Reviews, 2021, 125, 637-653.	6.1	39
114	Reduced Medial Prefrontal Responses to Social Interaction Images in Remitted Depression. Archives of General Psychiatry, 2012, 69, 37.	12.3	38
115	Drug-induced supersensitivity psychosis revisited: characteristics of relapse in treatment-compliant patients. Therapeutic Advances in Psychopharmacology, 2012, 2, 13-22.	2.7	37
116	Negative emotions towards others are diminished in remitted major depression. European Psychiatry, 2015, 30, 448-453.	0.2	37
117	Ritanserin facilitates anxiety in a simulated public-speaking paradigm. Journal of Psychopharmacology, 1997, 11, 225-231.	4.0	35
118	Risk-Taking Behavior in a Gambling Task Associated with Variations in the Tryptophan Hydroxylase 2 Gene: Relevance to Psychiatric Disorders. Neuropsychopharmacology, 2010, 35, 1109-1119.	5.4	35
119	Effects of risperidone, amisulpride and nicotine on eye movement control and their modulation by schizotypy. Psychopharmacology, 2013, 227, 331-345.	3.1	34
120	Neuroinflammation as measured by positron emission tomography in patients with recent onset and established schizophrenia: implications for immune pathogenesis. Molecular Psychiatry, 2021, 26, 5398-5406.	7.9	34
121	Differential Effects of Anaesthesia on the phMRI Response to Acute Ketamine Challenge. British Journal of Medicine and Medical Research, 2012, 2, 373-385.	0.2	34
122	Effect of acute tryptophan depletion on the response to controllable and uncontrollable noise stress. Biological Psychiatry, 2005, 57, 295-300.	1.3	33
123	Effect of quinolinic acid-induced lesions of the nucleus accumbens core on performance on a progressive ratio schedule of reinforcement: implications for inter-temporal choice. Psychopharmacology, 2008, 197, 339-350.	3.1	33
124	The HTR1A and HTR1B receptor genes influence stress-related information processing. European Neuropsychopharmacology, 2011, 21, 129-139.	0.7	33
125	Effect of disconnecting the orbital prefrontal cortex from the nucleus accumbens core on inter-temporal choice behaviour: A quantitative analysis. Behavioural Brain Research, 2008, 191, 272-279.	2.2	31
126	Better sexual acceptability of agomelatine (25 and 50 mg) compared to escitalopram (20 mg) in healthy volunteers. A 9-week, placebo-controlled study using the PRSexDQ scale. Journal of Psychopharmacology, 2015, 29, 1119-1128.	4.0	31

#	Article	IF	CITATIONS
127	The differential neurochemical bases of the behaviours elicited by serotonergic agents and by the combination of a monoamine oxidase inhibitor and L-DOPA. Neuropharmacology, 1981, 20, 123-130.	4.1	30
128	Familial and developmental abnormalities of frontal lobe function and neurochemistry in schizophrenia. Journal of Psychopharmacology, 1997, 11, 133-142.	4.0	30
129	The neuro/PsyGRID calibration experiment. Human Brain Mapping, 2012, 33, 373-386.	3.6	30
130	Minocycline as an adjunct for treatment-resistant depressive symptoms: study protocol for a pilot randomised controlled trial. Trials, 2015, 16, 410.	1.6	30
131	Naltrexone ameliorates functional network abnormalities in alcoholâ€dependent individuals. Addiction Biology, 2018, 23, 425-436.	2.6	30
132	A randomised clinical trial of methotrexate points to possible efficacy and adaptive immune dysfunction in psychosis. Translational Psychiatry, 2020, 10, 415.	4.8	30
133	Comparison of buspirone with diazepam and fluvoxamine on aversive classical conditioning in humans. Journal of Psychopharmacology, 1999, 13, 122-127.	4.0	29
134	Add-on clinical effects of simvastatin and ondansetron in patients with schizophrenia stabilized on antipsychotic treatment: pilot study. Therapeutic Advances in Psychopharmacology, 2014, 4, 110-116.	2.7	29
135	Effects of Different Stressors Are Modulated by Different Neurobiological Systems: The Role of GABA-A Versus CB1 Receptor Gene Variants in Anxiety and Depression. Frontiers in Cellular Neuroscience, 2019, 13, 138.	3.7	29
136	Peripheral immune markers and antipsychotic non-response in psychosis. Schizophrenia Research, 2021, 230, 1-8.	2.0	29
137	Choice between reinforcer delays versus choice between reinforcer magnitudes: Differential Fos expression in the orbital prefrontal cortex and nucleus accumbens core. Behavioural Brain Research, 2010, 213, 269-277.	2.2	28
138	Epistatic interaction of CREB1 and KCNJ6 on rumination and negative emotionality. European Neuropsychopharmacology, 2011, 21, 63-70.	0.7	28
139	Acute D3 Antagonist GSK598809 Selectively Enhances Neural Response During Monetary Reward Anticipation in Drug and Alcohol Dependence. Neuropsychopharmacology, 2017, 42, 1049-1057.	5.4	28
140	Deconstructing depression and negative symptoms of schizophrenia; differential and longitudinal immune correlates, and response to minocycline treatment. Brain, Behavior, and Immunity, 2021, 91, 498-504.	4.1	28
141	Variability in the Effect of 5-HTTLPR on Depression in a Large European Population: The Role of Age, Symptom Profile, Type and Intensity of Life Stressors. PLoS ONE, 2015, 10, e0116316.	2.5	28
142	The Imperial College Cambridge Manchester (ICCAM) platform study: An experimental medicine platform for evaluating new drugs for relapse prevention in addiction. Part A: Study description. Journal of Psychopharmacology, 2015, 29, 943-960.	4.0	27
143	Sample Size Estimation for Comparing Parameters Using Dynamic Causal Modeling. Brain Connectivity, 2012, 2, 80-90.	1.7	26
144	Neuronal Nitric Oxide Synthase (NOS1) Polymorphisms Interact with Financial Hardship to Affect Depression Risk. Neuropsychopharmacology, 2014, 39, 2857-2866.	5.4	26

#	Article	IF	CITATIONS
145	Impulsivity in abstinent alcohol and polydrug dependence: a multidimensional approach. Psychopharmacology, 2016, 233, 1487-1499.	3.1	26
146	Subgenual Cingulate–Amygdala Functional Disconnection and Vulnerability to Melancholic Depression. Neuropsychopharmacology, 2016, 41, 2082-2090.	5.4	26
147	Acute naltrexone does not remediate frontoâ€striatal disturbances in alcoholic and alcoholic polysubstanceâ€dependent populations during a monetary incentive delay task. Addiction Biology, 2017, 22, 1576-1589.	2.6	26
148	Timeâ€dependent neuronal changes associated with craving in opioid dependence: an <scp>fMRI</scp> study. Addiction Biology, 2018, 23, 1168-1178.	2.6	26
149	Detection of the acute effects of hydrocortisone in the hippocampus using pharmacological fMRI. European Neuropsychopharmacology, 2012, 22, 867-874.	0.7	25
150	Rumination in migraine: Mediating effects of brooding and reflection between migraine and psychological distress. Psychology and Health, 2016, 31, 1481-1497.	2.2	24
151	Clozapine monotherapy for catatonic schizophrenia: should clozapine be the treatment of choice, with catatonia rather than psychosis as the main therapeutic index?. Journal of Psychopharmacology, 2005, 19, 432-433.	4.0	23
152	Minocycline and celecoxib as adjunctive treatments for bipolar depression: a study protocol for a multicenter factorial design randomized controlled trial. Neuropsychiatric Disease and Treatment, 2017, Volume 13, 1-8.	2.2	23
153	Distinct effects of folate pathway genes MTHFR and MTHFD1L on ruminative response style: a potential risk mechanism for depression. Translational Psychiatry, 2016, 6, e745-e745.	4.8	23
154	Cortical serotonin receptor subtypes after lesion of ascending cholinergic neurones in rat. Neuroscience Letters, 1985, 60, 261-265.	2.1	22
155	Abnormal neural oscillations in schizotypy during a visual working memory task: Support for a deficient top-down network?. Neuropsychologia, 2011, 49, 2866-2873.	1.6	22
156	Evaluation of state and trait biomarkers in healthy volunteers for the development of novel drug treatments in schizophrenia. Journal of Psychopharmacology, 2011, 25, 1207-1225.	4.0	22
157	Interictal SPECT in patients with mesial temporal lobe epilepsy and psychosis: a case-control study. Psychiatry Research - Neuroimaging, 2005, 138, 75-84.	1.8	21
158	Effect of quinolinic acid-induced lesions of the subthalamic nucleus on performance on a progressive-ratio schedule of reinforcement: A quantitative analysis. Behavioural Brain Research, 2008, 195, 223-230.	2.2	21
159	The neural basis of conceptual–emotional integration and its role in major depressive disorder. Social Neuroscience, 2013, 8, 417-433.	1.3	21
160	The effects of ketamine and risperidone on eye movement control in healthy volunteers. Translational Psychiatry, 2013, 3, e334-e334.	4.8	21
161	TOMM40 rs2075650 May Represent a New Candidate Gene for Vulnerability to Major Depressive Disorder. Neuropsychopharmacology, 2014, 39, 1743-1753.	5.4	21
162	A novel resting-state functional magnetic resonance imaging signature of resilience to recurrent depression. Psychological Medicine, 2017, 47, 597-607.	4.5	21

#	Article	IF	CITATIONS
163	T regulatory cells as a potential therapeutic target in psychosis? Current challenges and future perspectives. Brain, Behavior, & Immunity - Health, 2021, 17, 100330.	2.5	21
164	Variants in the <i><scp>CNR1</scp></i> gene predispose to headache with nausea in the presence of life stress. Genes, Brain and Behavior, 2017, 16, 384-393.	2.2	20
165	A Unique Brain Connectome Fingerprint Predates and Predicts Response to Antidepressants. IScience, 2020, 23, 100800.	4.1	19
166	Arousal related to excretion of noradrenaline metabolites and clinical aspects of unmedicated chronic schizophrenic patients. Journal of Psychiatric Research, 1979, 15, 57-65.	3.1	18
167	The NR1 N-Methyl-d-Aspartate Subunit and Brain-derived Neurotrophic Factor in Temporal Lobe Epilepsy Hippocampus: A Comparison of Patients with and without Coexisting Psychiatric Symptoms. Epilepsia, 2007, 48, 071005074820001-???.	5.1	18
168	Effects of acute tryptophan depletion on central processing of <scp>CT</scp> â€ŧargeted and discriminatory touch in humans. European Journal of Neuroscience, 2016, 44, 2072-2083.	2.6	18
169	Financial difficulties but not other types of recent negative life events show strong interactions with 5-HTTLPR genotype in the development of depressive symptoms. Translational Psychiatry, 2016, 6, e798-e798.	4.8	18
170	Effects of naltrexone are influenced by childhood adversity during negative emotional processing in addiction recovery. Translational Psychiatry, 2017, 7, e1054-e1054.	4.8	18
171	Genome-wide association analysis reveals KCTD12 and miR-383-binding genes in the background of rumination. Translational Psychiatry, 2019, 9, 119.	4.8	18
172	[3H]etorphine binding in rat striatum following lesions of the raphe nuclei. European Journal of Pharmacology, 1983, 91, 119-121.	3.5	17
173	Optimizing antidepressant treatment: efficacy and tolerability. International Clinical Psychopharmacology, 2002, 17, S13-S24.	1.7	17
174	Amoxapine as an Antipsychotic. Journal of Clinical Psychopharmacology, 2007, 27, 575-581.	1.4	17
175	Quantitative analysis of the effect of lesions of the subthalamic nucleus on intertemporal choice: further evidence for enhancement of the incentive value of food reinforcers. Behavioural Pharmacology, 2009, 20, 437-446.	1.7	17
176	Assessment of the impact of the scanner-related factors on brain morphometry analysis with Brainvisa. BMC Medical Imaging, 2011, 11, 23.	2.7	17
177	Core dysfunction in schizophrenia: electrophysiology trait biomarkers. Acta Psychiatrica Scandinavica, 2012, 126, 59-71.	4.5	17
178	Evidence in cortical folding patterns for prenatal predispositions to hallucinations in schizophrenia. Translational Psychiatry, 2020, 10, 387.	4.8	17
179	Total agenesis of the corpus callosum in a patient with childhood-onset schizophrenia. Arquivos De Neuro-Psiquiatria, 2007, 65, 1216-1219.	0.8	17
180	Relationships between hyponeophagia, diazepam sensitivity and benzodiazepine receptor binding in eighteen rat genotypes. Pharmacology Biochemistry and Behavior, 1984, 20, 845-847.	2.9	16

#	Article	IF	CITATIONS
181	Genetic variants in the catecholâ€ <i>o</i> â€methyltransferase gene are associated with impulsivity and executive function: Relevance for major depression. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2012, 159B, 928-940.	1.7	16
182	The ICCAM platform study: An experimental medicine platform for evaluating new drugs for relapse prevention in addiction. Part B: fMRI description. Journal of Psychopharmacology, 2017, 31, 3-16.	4.0	16
183	Gender Differences and the Effects of Ketamine in Healthy Volunteers. Journal of Psychopharmacology, 2004, 18, 337-339.	4.0	15
184	New visual information processing abnormality biomarkers for the diagnosis of schizophrenia. Expert Opinion on Medical Diagnostics, 2011, 5, 357-368.	1.6	14
185	Enhanced subgenual cingulate response to altruistic decisions in remitted major depressive disorder. NeuroImage: Clinical, 2014, 4, 701-710.	2.7	14
186	A randomised double-blind placebo-controlled 12- week feasibility trial of methotrexate added to treatment as usual in early schizophrenia: study protocol for a randomised controlled trial. Trials, 2015, 16, 9.	1.6	14
187	A new stress sensor and risk factor for suicide: the T allele of the functional genetic variant in the GABRA6 gene. Scientific Reports, 2017, 7, 12887.	3.3	14
188	The UKB envirome of depression: from interactions to synergistic effects. Scientific Reports, 2019, 9, 9723.	3.3	14
189	Reduced d-[3H]aspartate binding in Down's syndrome brains. Brain Research, 1989, 484, 273-278.	2.2	13
190	Mirtazapine antagonises the subjective, hormonal and neuronal effects of m-chlorophenylpiperazine (mCPP) infusion: A pharmacological-challenge fMRI (phMRI) study. NeuroImage, 2011, 58, 497-507.	4.2	13
191	5-HT and mechanisms of defence. Author's response. Journal of Psychopharmacology, 1991, 5, 339-341.	4.0	12
192	A comparison of permutation and parametric testing for between group effective connectivity differences using DCM. Neurolmage, 2010, 50, 509-515.	4.2	12
193	Shared changes in gene expression in frontal cortex of four genetically modified mouse models of depression. European Neuropsychopharmacology, 2011, 21, 3-10.	0.7	12
194	Association of ATP6V1B2 rs1106634 with lifetime risk of depression and hippocampal neurocognitive deficits: possible novel mechanisms in the etiopathology of depression. Translational Psychiatry, 2016, 6, e945-e945.	4.8	12
195	NewMood: A productive European model of collaboration for translational research in depression. European Neuropsychopharmacology, 2011, 21, 1-2.	0.7	11
196	Ondansetron and simvastatin added to treatment as usual in patients with schizophrenia: study protocol for a randomized controlled trial. Trials, 2013, 14, 101.	1.6	11
197	An investigation into aripiprazole's partial D2 agonist effects within the dorsolateral prefrontal cortex during working memory in healthy volunteers. Psychopharmacology, 2016, 233, 1415-1426.	3.1	11
198	Naltrexone differentially modulates the neural correlates of motor impulse control in abstinent alcoholâ€dependent and polysubstanceâ€dependent individuals. European Journal of Neuroscience, 2019, 50, 2311-2321.	2.6	11

#	Article	IF	CITATIONS
199	Neuropsychological performance and noradrenaline function in chronic fatigue syndrome under conditions of high arousal. Psychopharmacology, 2002, 163, 166-173.	3.1	10
200	Disturbances across whole brain networks during reward anticipation in an abstinent addiction population. NeuroImage: Clinical, 2020, 27, 102297.	2.7	10
201	P2RX7 gene variation mediates the effect of childhood adversity and recent stress on the severity of depressive symptoms. PLoS ONE, 2021, 16, e0252766.	2.5	10
202	Right-hemisphere encephalopathy in elderly subjects with schizophrenia: evidence from neuropsychological and brain imaging studies. Psychopharmacology, 2003, 169, 367-375.	3.1	9
203	Childhood Adversity Moderates the Effects of HTR2A Epigenetic Regulatory Polymorphisms on Rumination. Frontiers in Psychiatry, 2019, 10, 394.	2.6	9
204	Hormonal response to L-tryptophan infusion: Effect of propranolol. Psychoneuroendocrinology, 1990, 15, 309-312.	2.7	8
205	The benefit of minocycline on negative symptoms in early-phase psychosis in addition to standard care - extent and mechanism (BeneMin): study protocol for a randomised controlled trial. Trials, 2015, 16, 71.	1.6	8
206	Effects of Acute Ketamine Infusion on Visual Working Memory: Event-Related Potentials. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2017, 2, 253-262.	1.5	8
207	THE PSYCHOPHYSIOLOGICAL RESPONSES OF PTSD PATIENTS: HABITUATION, RESPONSES TO STRESSFUL AND NEUTRAL VIGNETTES AND ASSOCIATION WITH TREATMENT OUTCOME. Behavioural and Cognitive Psychotherapy, 2002, 30, 129-142.	1.2	7
208	MHPG excretion in endogenous depression: Relationship to clinical state and the effects of ECT. Psychopharmacology, 1985, 87, 442-448.	3.1	6
209	Cerebral oxidative metabolism mapping in four genetic mouse models of anxiety and mood disorders. Behavioural Brain Research, 2019, 356, 435-443.	2.2	6
210	Genetic analyses of the endocannabinoid pathway in association with affective phenotypic variants. Neuroscience Letters, 2021, 744, 135600.	2.1	6
211	Inflamed Mind: Multiple Genetic Variants of IL6 Influence Suicide Risk Phenotypes in Interaction With Early and Recent Adversities in a Linkage Disequilibrium-Based Clumping Analysis. Frontiers in Psychiatry, 2021, 12, 746206.	2.6	6
212	A replication study separates polymorphisms behind migraine with and without depression. PLoS ONE, 2021, 16, e0261477.	2.5	6
213	Deakin et al. reply. Trends in Pharmacological Sciences, 1993, 14, 398.	8.7	5
214	Spatiotemporal brain activation pattern following acute citalopram challenge is dose dependent and associated with neuroticism: A human phMRI study. Neuropharmacology, 2020, 170, 107807.	4.1	5
215	Trial failures of anti-inflammatory drugs in depression – Authors' reply. Lancet Psychiatry,the, 2020, 7, 837-838.	7.4	5
216	Serotonin in panic, anxiety and depression. European Neuropsychopharmacology, 1991, 1, 358-360.	0.7	4

#	Article	IF	CITATIONS
217	Olanzapine for Recurrent Aggression in a Patient with Temporal Lobe Epilepsy who had Temporal Lobectomy. Journal of Psychopharmacology, 2003, 17, 350-351.	4.0	4
218	Application of SWATH mass spectrometry in the identification of circulating proteins does not predict future weight gain in early psychosis. Clinical Proteomics, 2020, 17, 38.	2.1	4
219	"Out, out, brief candle! Life's but a walking shadow†5-HTTLPR Is Associated With Current Suicidal Ideation but Not With Previous Suicide Attempts and Interacts With Recent Relationship Problems. Frontiers in Psychiatry, 2020, 11, 567.	2.6	4
220	Financial Stress Interacts With CLOCK Gene to Affect Migraine. Frontiers in Behavioral Neuroscience, 2019, 13, 284.	2.0	4
221	Cognitive function in early-phase schizophrenia-spectrum disorder: IQ subtypes, brain volume and immune markers. Psychological Medicine, 2022, , 1-10.	4.5	3
222	Use of MRI for measuring structures in frozen postmortem brain. Brain Research Bulletin, 1995, 38, 457-460.	3.0	2
223	Chronic alcohol exposure differentially modulates structural and functional properties of amygdala: A crossâ€sectional study. Addiction Biology, 2021, 26, e12980.	2.6	2
224	Minocycline for negative symptoms of schizophrenia and possible mechanistic actions: the BeneMin RCT. Efficacy and Mechanism Evaluation, 2019, 6, 1-66.	0.7	2
225	Genetic effects on educational attainment in Hungary. Brain and Behavior, 2022, 12, e2430.	2.2	2
226	Analysis of connectivity in the resting state of the default mode of brain function: a major role for the cerebellum?. International Journal of Modelling, Identification and Control, 2010, 9, 236.	0.2	1
227	Assessing adjunctive treatments for bipolar depression. Lancet Psychiatry,the, 2020, 7, 478-479.	7.4	1
228	Biology of Perseverative Negative Thinking: The Role of Timing and Folate Intake. Nutrients, 2021, 13, 4396.	4.1	1
229	Impaired verbal memory function is related to anterior cingulate glutamate levels in schizophrenia: findings from the STRATA study. , 2022, 8, .		1
230	From laboratory to clinic, a clinical perspective on animal models of depression. European Neuropsychopharmacology, 1991, 1, 302-304.	0.7	0
231	Agomelatine: a new treatment for depression. Future Prescriber, 2009, 10, 14-19.	0.1	0
232	Contributing factors in the comorbidity of depression and pain: A Bayesian approach. European Neuropsychopharmacology, 2019, 29, S290-S291.	0.7	0
233	Effectiveness of Immunotherapies for Psychotic Disorders. , 2021, , 96-108.		0